San Diego, CA
Alzheimer’s disease is one of the most important health challenges facing aging populations worldwide. The 6th annual CtaD conference will relate experiences from international teams covering every stage of clinical trials in Alzheimer’s Disease. From animal models to human trials, CtaD 2013 provides an opportunity to learn about the latest results in drug trials as well as important topics such as internet screening of cognition to recruit for clinical trials, designing drug trials taking into account neuropsychiatric symptoms of AD, down syndrome as well as ethical issues and methodological considerations. BioClinica is a sponsor of this event.
Vice President and Executive Director Chahin Pachai, PhD, will attend the meeting and will display, in conjunction with other authors including Medical Affairs Scientist Hui Jing Yu, PhD, the following posters:
- Predictive Value of Baseline Hippocampal Volumes and Brain Amyloid Burden on Atrophy Rates for Predementia Alzheimer’s Disease Subjects with Data from Study CN156-018 and ADNI-1
- Comparison of Intracranial Volume Quantification Based on 2D T2* and 3D T1-Weighted MRI Sequences
- Comparison of Boundary Shift Integral and Tensor Based Morphometry to Assess Volume Changes on Whole Brain and Lateral Ventricles – Application to Study CN156-018
- Longitudinal Volumetric Changes in Study CN156-018, as Compared to ADNI-1